Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats by Yan Zhang et al.
Zhang et al. Lipids in Health and Disease 2014, 13:35
http://www.lipidworld.com/content/13/1/35RESEARCH Open AccessImpact of currently prescribed lipid-lowering
drugs on plasma PCSK9 concentration: single or
in combination study in rats
Yan Zhang†, Jun Liu†, Sha Li, Rui-Xia Xu, Jing Sun and Jian-Jun Li*Abstract
Background: An emerging data suggested a significant impact of statins on PCSK9 concentration, while the rapid
impacts of other lipid-lowering drugs such as ezetimibe and xuezhikang alone or in combination on PCSK9 and
lipid profile have not been assessed. This study aims to investigate whether an enhanced PCSK9 concentration by
single or combined therapy of lipid-lowering drugs currently used precedes the changes of lipid profile in rats.
Methods: Sixty-three rats were randomly divided into six groups and orally administrated with placebo (N = 13),
ezetimibe 10 mg/kg daily, Xuezhikang 1200 mg/kg daily, ezetimibe 10 mg/kg plus Xuezhikang 1200 mg/kg daily,
pitavastatin 10 mg/kg daily or pitavastatin 10 mg/kg plus ezetimibe 10 mg/kg daily for 3 days (N = 10 for each
group respectively). Blood samples were obtained at day 3 after orally administration. Plasma PCSK9 levels were
determined by ELISA and lipid profile were measured by enzymatic assay.
Results: Ezetimibe, Xuezhikang and pitavastatin alone and Xuezhikang plus ezetimibe as well as pitavastatin
plus ezetimibe increased PCSK9 levels by 124%, 56%, 111%, 63% and 204% respectively (p < 0.05 compared with
placebo). However, Xuezhikang plus ezetimibe did not enhance greater PCSK9 levels compared to monotherapy.
Ezetimibe and pitavastatin in combination induced higher PCSK9 levels than pitavastatin monotherapy or
co-therapy with ezetimibe plus Xuezhikang. There was no significant difference between any groups with
regard to lipid profile levels at day 3 (P > 0.05).
Conclusions: Elevated PCSK9 concentration by ezetimibe, Xuezhikang and pitavastatin alone or in combination was
found prior to the alterations of lipid profile in rats. Combination of Xuezhikang and ezetimibe significantly
attenuated increase in PCSK9 compared to ezetimibe plus pitavastatin, suggesting that the former combination
may be better than the latter in future clinical application.
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Proprotein convertase subtilisin/kexin type 9 (PCSK9) is
a secreted protease synthesized mainly in the liver, which
binds directly to the epidermal growth factor repeat A of
the low-density lipoprotein receptor (LDLR) and subse-
quently targets it for degradation [1]. This process re-
sults in increased serum LDL-cholesterol (LDL-C) levels
in the circulation [2]. Gain-of-function mutations in the* Correspondence: lijianjun938@yahoo.com
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unless otherwise stated.PCSK9 gene are associated with autosomal dominant
hypercholesterolemia and premature cardiovascular dis-
ease [3,4]. Conversely, loss-of-function mutations of the
PCSK9 gene linked to low LDL-C levels and a dramatic-
ally reduced risk for coronary heart disease [5]. There-
fore, PCSK9 has been considered as another target for
dyslipidemia and atherosclerosis [6].
Recently, several studies indicated that statins (HMG-
CoA reductase inhibitors) could upregulate PCSK9 levels
in humans [7-9], which may attenuate the beneficial
effects of statins [10]. It was recently postulated that sta-
tins increase the activity of sterol regulator element–
binding protein 2 (SREBP-2), which is a transcriptionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[11], and eventually induces elevated expression and se-
cretion of PCSK9 protein. In addition, other common
prescribed lipid-lowering drugs, ezetimibe, Xuezhikang
are widely used as alone or in combination for the
management of dyslipidemia. For example, ezetimibe is
an inhibitor of intestinal cholesterol absorption, which
could decrease LDL-C by approximately 20% when ad-
ministered alone [12] and when combined with statin
could achieve 15% more decrease in LDL-C concentra-
tions compared with statin alone [13]. However, a few
reports about whether ezetimibe could exert similar ef-
fects on PCSK9 as statins are inconsistent [14,15].
Extracts of red yeast rice have been widely used for
therapy of patients with cardiovascular disorders in
China for centuries. Xuezhikang, a partially purified ex-
tract of fermented red yeast rice, contains 13 kinds of
natural statins (high amounts of lovastatin), unsaturated
fatty acids, ergosterol, flavonoids, and some other com-
ponents [16,17]. A systematic review demonstrated that
Xuezhikang exerted significant lipid-lowering effects in
the treatment of hyperlipidemia [18]. Recently, clinical
studies indicated that Xuezhikang could be used as an
alternative therapy for patients intolerant of statin [19].
However, there are limited data to evaluate the impact
of Xuezhikang on the PCSK9 levels. Although previous
studies have implied that lipid-lowering drugs have
short-term effects on PCSK9 in humans [20], study in-
vestigating whether the impact of currently used lipid-
lowering drugs on PCSK9 levels prior to the changes of
lipid profile is still limited. Moreover, the impacts of
lipid-lowering drugs in combination on PCSK9 has less
been evaluated till now.
Therefore, the aim of the present study was to evalu-
ate: 1) whether the increase of PCSK9 concentration is
prior to the decrease of LDL-C levels; 2) the rapid effects
of different lipid-lowering drugs on PCSK9 concentra-
tion; 3) the different impacts of lipid-lowering drugs in
combination on PCSK9 concentration.
Materials and methods
Animal preparation
Male Sprague–Dawley rats, weighing 180–220 g, were
fed in a temperature-conditioned (22-24°C) room with
alternating 12 h light/dark cycles and allowed them free
access to food and water for 3 days to get familiar
with the environment. At the start of the study, 63 rats
were randomly assigned to six groups: (1) placebo group
(N = 13, orally administrated with normal saline), (2)
ezetimibe group (N = 10, orally administrated with ezeti-
mibe 10 mg/kg daily), (3) Xuezhikang group (N = 10, or-
ally administrated with Xuezhikang 1200 mg/kg daily),
(4) ezetimibe plus Xuezhikang group (N = 10, orally ad-
ministrated with ezetimibe 10 mg/kg plus Xuezhikang1200 mg/kg daily), (5) pitavastatin group (N = 10, orally
administrated with pitavastatin 10 mg/kg daily), and
(6) pitavastatin plus ezetimibe group (N = 10, orally ad-
ministrated with pitavastatin 10 mg/kg plus ezetimibe
10 mg/kg daily). This study was conducted in accord-
ance with the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health,
and all experimental procedures and protocols were ap-
proved by the Care of Experimental Animals Committee
of Fuwai Hospital, Chinese Academy of Medical Sci-
ences and Peking Union Medical College.
Blood sample and analysis
After 3 days orally administration, prior to sacrifice,
2 ml fasting blood were collected from the inferior vena
cava and transferred to K2 EDTA tubes. Immediately
after blood sampling, the animals were euthanized by an
overdose of pentobarbital sodium. The blood samples
were centrifuged, and the plasma was stored at −80°C
until the analyses were performed. Concentrations of
serum total cholesterol (TC), triglycerides (TG), high
density lipoprotein cholesterol (HDL-C) and LDL-C
were determined on an automatic biochemistry analyzer
(Hitachi 7150, Tokyo, Japan). Plasma PCSK9 concentra-
tions were measured using a high-sensitivity, quantita-
tive sandwich enzyme immunoassay (Quantikine ELISA,
R&D Systems Europe Ltd). The lower limit of detection
was 0.096 ng/ml.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD) and categorical variables were presented
as frequent count and percentages. The comparison of
inter-group analysis of PCSK9 and lipid profile levels
was performed by unpaired two-tailed t-test and one
way ANOVA. A P value of less than 0.05 was considered
statistical significance. The SPSS 19.0 statistical software
package (SPSS Inc., Chicago, IL, USA) was used for all
of the statistical analysis.
Results
The changes of lipid profile
As shown in Table 1, there was no significant difference
in lipid profile among rats receiving placebo, ezetimibe,
Xuezhikang, pitavastatin, ezetimibe plus Xuezhikang, or
pitavastatin plus ezetimibe at day 3 (p > 0.05).
Rapid effects of lipid-lowering drugs on plasma PCSK9
concentrations
As shown in Figures 1 and 2, at day 3, PCSK9 levels in-
creased from 296.29 ± 112.95 ng/ml to 664.76 ± 331.73 ng/
ml in rats receiving ezetimibe 10 mg/kg daily treatment
(124%; p < 0.05 vs. placebo). In rats treated with Xuezhi-
kang 1200 mg/kg daily, PCSK9 levels increased from













PCSK9 ng/ml 296.29 ± 112.95 664.76 ± 331.73* 461.20 ± 124.96* 482.86 ± 130.29* 626.16 ± 221.48* 901.35 ± 235.56*#Δ
TG mmol/l 0.76 ± 0.72 0.51 ± 0.17 1.38 ± 0.12 1.26 ± 0.29 0.44 ± 0.12 0.91 ± 0.18
TC mmol/l 2.13 ± 0.26 2.44 ± 0.40 2.25 ± 0.37 2.19 ± 0.40 2.50 ± 0.40 2.39 ± 0.33
HDL-C mmol/l 1.04 ± 0.29 1.31 ± 0.29 1.04 ± 0.29 0.94 ± 0.20 1.25 ± 0.27 1.22 ± 0.27
LDL-C mmol/l 0.53 ± 0.14 0.51 ± 0.15 0.45 ± 0.07 0.42 ± 0.04 0.64 ± 0.18 0.48 ± 0.09
Data are expressed as means ± SD. * p < 0.05 versus placebo group. # p < 0.05 versus pitavastatin group. Δp < 0.05 versus Xuezhikang + ezetimibe group.
PCSK9 = proprotein convertase subtilisin/kexin type 9; TG = triglycerides; TC = total cholesterol; HDL-C = high density lipoprotein cholesterol; LDL-C = low density
lipoprotein cholesterol.
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crease, p < 0.05 vs. placebo). In rats with pitavastatin
10 mg/kg daily treatment, PCSK9 increased from 296.29 ±
112.95 ng/ml to 626.16 ± 221.48 ng/ml (111% increase,
p < 0.05 vs. placebo). The combination of ezetimibe 10 mg/
kg daily plus Xuezhikang 1200 mg/kg daily resulted in an
increase of PCSK9 levels by 63% (296.29 ± 112.95 to
482.86 ± 130.29 ng/ml). Pitavastatin 10 mg/kg daily and
ezetimibe 10 mg/kg daily in combination resulted in an in-
crease of PCSK9 by 204% (296.29 ± 112.95 to 901.35 ±
235.56 ng/ml; p < 0.05 vs. placebo).
Combination of ezetimibe plus Xuezhikang, ezetimibe
plus pitavastatin on plasma PCSK9 concentrations
As shown in Table 1, at day 3, in combination of ezeti-
mibe and Xuezhikang did not induce greater increase of
PCSK9 concentrations than monotherapy with either
agent (p > 0.05). However, as shown in Figures 3 and 4,
the PCSK9 concentrations among rats treated with ezeti-
mibe plus pitavastatin was much higher than monother-
apy with pitavastatin or the co-therapy of ezetimibe plus
Xuezhikang (p < 0.05).
Discussion
The current experiment explored the rapid effects of the
3 currently prescribed lipid-lowering drugs, pitavastatin,
ezetimibe and Xuezhikang, alone and in combination,
on PCSK9 and lipid profile concentrations in rats in
a very short period. The main finding of this study isFigure 1 PCSK9 levels during the treatment with placebo, ezetimibe,
pitavastatin plus ezetimibe. * p < 0.05 versus placebo group. XZK: Xuezhthat ezetimibe, Xuezhikang and pitavastatin alone and
Xuezhikang plus ezetimibe as well as pitavastatin plus
ezetimibe, all could significantly increase the PCSK9
levels at day 3, when the lipid profile had no obvious de-
creases. In addition, combination of ezetimibe 10 mg/kg
and Xuezhikang 1200 mg/kg daily did not further en-
hance PCSK9 levels compared to the monotherapy,
while ezetimibe 10 mg/kg and pitavastatin 10 mg/kg
daily in combination induced higher PCSK9 levels than
monotherapy with pitavastatin or co-therapy with ezeti-
mibe plus Xuezhikang.
It has been well established that PCSK9 promotes the
degradation of LDLR and could limit the beneficial ef-
fects of lipid-lowering drugs [1]. Several studies indi-
cated that lipid-lowering drugs could elevate plasma
PCSK9 concentrations and may have rapid impact on
PCSK9 levels [20]. In our present study, we confirmed
previous studies and provided novel additional import-
ant information regarding the lipid-lowering drugs on
plasma PCSK9. This study, for the first time, indicated
that the enhancement of PCSK9 levels preceded the
changes of lipid profile. Therefore, it is reasonable to
deduce that patients with dyslipidemia may get more
benefits from PCSK9 inhibitors, such as monoclonal
antibody [21], if it be used before the application of
lipid-lowering drugs in clinical practice. Although com-
monly prescribed lipid-lowering drugs may up-regulate
both the LDLR and PCSK9 genes by activating SREBP-2
[11], the PCSK9 gene might respond much earlier thanXuezhikang, Xuezhikang plus ezetimibe, pitavastatin and
ikang.
Figure 2 Mean percentage changes from placebo in PCSK9 levels during the treatment with ezetimibe, Xuezhikang, Xuezhikang plus
ezetimibe, pitavastatin and pitavastatin plus ezetimibe. XZK: Xuezhikang.
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changes of PCSK9 levels preceded the lipid profile.
Currently, combination of two different lipid-lowering
drugs is frequently prescribed in controlling dyslipid-
emia. Statin plus ezemtibe in combination is the most
commonly used style. In recent years, several researchers
have described the combination of statin and ezetimibe
on the increase of PCSK9 levels in humans. A recent
study conducted by Davignon et al. [22] demonstrated
that patients treated with statins alone had a 45% in-
crease in PCSK9 levels and those treated with statin plus
ezetimibe showed an approximately 77% increase in
PCSK9 concentrations. In our study, the PCSK9 levels
increased by 111% in rats administrated with pitavastatin
10 mg/kg daily, while added ezetimibe 10 mg/kg daily to
pitavastatin, the PCSK9 levels enhanced by 204%. How-
ever, little was known about the reason why ezetimibe
causes a further increase in PCSK9 levels. Since ezeti-
mibe exerts its effect by binding to Niemann-Pick
C1-Like 1, and thereby inhibiting intestinal cholesterol
absorption and subsequently results in reduced hepatic
cholesterol [23], it may be possible that this process is
accompanied by a feedback mechanism on transcription
factor SREBP-2. Furthermore, in mice models, Brandon
Ason et al. [15] applied qRT-PCR to analyze the expres-
sion of 361 genes involved in hepatic lipid metabolism
and found that many genes within the SREBP-2 pathway
were induced following ezetimibe treatment (2.5-foldFigure 3 PCSK9 levels during the treatment with ezetimibe, pitavasta
group. XZK: Xuezhikang.average induction relative to control) and were even fur-
ther induced by ezetimibe plus rosuvastatin combination
treatment (11-fold average induction relative to control).
This study provides theoretical evidences about the im-
pact of ezetimibe on plasma PCSK9 levels. In contrast,
Heiner K. Berthold et al. [14] indicated that when added
to simvastatin, ezetimibe does not cause an incremental
increase in PCSK9 concentrations, which conflicted
with our observations. However, this study explored the
14 days effect of ezetimibe-statin in combination on
plasma PCSK9 levels in humans, and different kinds of
statins were used in the two studies. Even so, for the
sake of exploring a thorough explanation of the mechan-
ism, further studies are warranted.
In our study, we also observed that combination of
ezetimibe 10 mg/kg and Xuezhikang 1200 mg/kg daily
did not bring a greater increase in PCSK9 levels than
monotherapy, and the PCSK9 levels was significantly
lower than co-therapy with ezetimibe plus pitavastatin.
Therefore, for patients who need an intensive lipid-
lowering therapy, the combination of Xuezhikang and
ezetimibe would be a better alternative therapy. This
combination could be a better strategy not only for
exerting good lipid-lowering effect on LDL-C, but also
for mitigating the adverse effects of lipid-lowering drugs
on PCSK9 in controlling dyslipidemia and atheroscler-
osis. At the present time, with regarding to the mecha-
nism by which ezetimibe plus Xuezhikang causes antin and pitavastatin plus ezetimibe. # p < 0.05 versus pitavastatin
Figure 4 PCSK9 levels during the treatment with Xuezhikang plus ezetimibe and pitavastatin plus ezetimibe. Δp < 0.05 versus
Xuezhikang plus ezetimibe group. XZK: Xuezhikang.
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therapy and co-therapy with ezetimibe plus pitavastatin
is unclear, but it may likely associated with the chemical
constituents of Xuezhikang. Xuezhikang, a Chinese trad-
itional medicine, is widely used as a lipid-lowering drug,
and its main components contain lovastatin, as well as
other useful substances [16-18]. Recent studies including
our data have shown that Xuezhikang has many pleio-
tropic effects, which could effectively modify not only
lipid profile but also inflammatory markers [24]. The in-
teractions among different constituents of Xuezhikang
and ezetimibe may influence the effect on PCSK9 levels,
but clinical trials and molecular mechanisms are needed
in the further studies.
For the past decade, PCSK9 has gained tremendous
attention. It is well-established that statin treatment ele-
vates plasma PCSK9 levels and, on the contrary, inhib-
ition of PCSK9 function enhances the lipid-lowering
effects of statins [25,26]. Among the various PCSK9 in-
hibitors, human data are available for monoclonal anti-
bodies against PCSK9 of which the two most advanced
are SAR236553/REGN727 and AMG 145. In a 12-week
phase II study of patients with LDL-C levels ≥ 100 mg/dl
on a stable dose of atorvastatin (10, 20, or 40 mg/day),
add-on of SAR236553/REGN727 (doses 50–150 mg) ad-
ministered subcutaneously every 2 weeks resulted in
LDL-C reductions of 40–72% [27]. The LAPLACE-TIMI
trial evaluated patients with documented hypercholester-
olemia, while on a statin with or without ezetimibe treat-
ment. The data had shown reductions of LDL-C by
41.8% to 66.1% when administrated AMG 145 at 70, 105
and 140 mg every 2 weeks, with acceptable safety and
tolerability [21]. Combining our findings and previous
studies together may suggest that, not only statins, but
also ezetimibe and Xuezhikang could increase plasma
PCSK9 levels, and this effects occurred before the
changes of lipid-profile, which strongly suggest that
PCSK9 inhibitors should be combined with the cur-
rently prescribed lipid-lowering drugs to result in fur-
ther LDL-C lowering effect, and it would be better to
be used prior to lipid-lowering drugs. Moreover, ourdata also provides additional information with respect
to combination of ezetimibe plus Xuezhikang may be
a better choice than ezetimibe plus pitavastatin in
clinical practice.
There are several limitations in the present study.
First, we did not observe the long-term effect of dif-
ferent lipid-lowering drugs, alone and in combination,
on plasma PCSK9 and lipid-profile concentrations.
Second, we did not explore the molecular mecha-
nisms of the phenomenon. Hence, further studies are
needed.
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